Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
The era of the aging society has arrived, and this is accompanied by an increase in the absolute numbers of patients with neurological disorders, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Such neurological disorders are serious costly diseases that have a significant impact on society, both globally and socially. Gene therapy has great promise for the treatment of neurological disorders, but only a few gene therapy drugs are currently available. Delivery to the brain is the biggest hurdle in developing new drugs for the central nervous system (CNS) diseases and this is especially true in the case of gene delivery. Nanotechnologies such as viral and non-viral vectors allow efficient brain-targeted gene delivery systems to be created. The purpose of this review is to provide a comprehensive review of the current status of the development of successful drug delivery to the CNS for the treatment of CNS-related disorders especially by gene therapy. We mainly address three aspects of this situation: (1) blood-brain barrier (BBB) functions; (2) adeno-associated viral (AAV) vectors, currently the most advanced gene delivery vector; (3) non-viral brain targeting by non-invasive methods.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O'Keeffe, S., Phatnani, H. P., Guarnieri, P., Caneda, C., Ruderisch, N., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1860-14.2014 · Cited by 4,875
Daneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq
Zeisel, A., Muñoz-Manchado, A. B., Codeluppi, S., Lönnerberg, P., La Manno, G., Juréus, A., Marques, S., Munguba, H., He, L., Betsholtz, C., et al. (2015) · Science · doi:10.1126/science.aaa1934 · Cited by 3,124
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Pericytes regulate the blood–brain barrier
Armulik, A., Genové, G., Mäe, M., Nisancioglu, M. H., Wallgard, E., Niaudet, C., He, L., Norlin, J., Lindblom, P., Strittmatter, K., et al. (2010) · Nature · doi:10.1038/nature09522 · Cited by 2,843 · cited 1×
“Pericytes are able to modulate BBB integrity (increase of transendothelial electrical resistance (TEER)), transcytosis rate, and the expression of efflux pumps [95,96].”
BackgroundThe blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises
Armulik, A., Genové, G., & Betsholtz, C. (2011) · Developmental Cell · doi:10.1016/j.devcel.2011.07.001 · Cited by 2,653
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“In AD treatment, the main strategy is to remove extracellular amyloid since amyloid deposition is thought to be central event in AD [18].”
BackgroundSingle-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381 · cited 2×
“However, most of the gene vectors used in the above reports are administered by invasive local injection, and such brain targeting continues to be a challenge, although Zolgensma, an intravenously administered gene therapy for SMA, was approved in 2019 [24,25].”
BackgroundAzevedo, F. A. C., Carvalho, L. R. B., Grinberg, L. T., Farfel, J. M., Ferretti, R. E. L., Leite, R. E. P., Filho, W. J., Lent, R., & Herculano‐Houzel, S. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.21974 · Cited by 2,337 · cited 1×
“Astrocytes are star-shaped glial cells that constitute a large portion of brain cells and the glia is not homogenously distributed in the brain [83,84].”
BackgroundBlood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312 · cited 2×
“The specific receptors and transporters that are expressed on the BBB make this possible [58,101].”
BackgroundManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 2×
“AAV9 1 Neonatal mice→neurons [216] Adult mice→astrocytes Used as the vector of Zolgensma”
BackgroundMethodAdenosine Receptors as Therapeutic Targets
Jacobson, K. A., & Gao, Z.-G. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1983 · Cited by 1,431 · cited 1×
“including CNS disorders [280], and it has been reported that the activation of adenosine receptors could elevate the permeability of the BBB in vivo [279].”
BackgroundDunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410 · cited 1×
“Since 2008, however, gene therapy development has been rekindled with the development of improved vectors, and gene therapy has now become a more active area of research [10].”
BackgroundAdeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
The global burden of neurological disorders: translating evidence into policy
Feigin, V. L., Vos, T., Nichols, E., Owolabi, M. O., Carroll, W. M., Dichgans, M., Deuschl, G., Parmar, P., Brainin, M., & Murray, C. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30411-9 · Cited by 1,303
Schöttler, S., Becker, G., Winzen, S., Steinbach, T., Mohr, K., Landfester, K., Mailänder, V., & Wurm, F. R. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.330 · Cited by 1,272
Transvascular delivery of small interfering RNA to the central nervous system
Kumar, P., Wu, H., McBride, J. L., Jung, K.-E., Hee Kim, M., Davidson, B. L., Kyung Lee, S., Shankar, P., & Manjunath, N. (2007) · Nature · doi:10.1038/nature05901 · Cited by 1,246
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220 · cited 1×
“APOE4 increases brain amyloid-β (Aβ) pathology relative to other APOE isoforms, and the absence of APOE is protective [20].”
BackgroundIntranasal delivery of biologics to the central nervous system
Lochhead, J. J., & Thorne, R. G. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.002 · Cited by 1,214
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
Tomac, A., Lindqvist, E., Lin, L.-F. H., Ögren, S. O., Young, D., Hoffer, B. J., & Olson, L. (1995) · Nature · doi:10.1038/373335a0 · Cited by 1,079
von Bartheld, C. S., Bahney, J., & Herculano‐Houzel, S. (2016) · Journal of Comparative Neurology · doi:10.1002/cne.24040 · Cited by 1,063
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain
Deverman, B. E., Pravdo, P. L., Simpson, B. P., Kumar, S. R., Chan, K. Y., Banerjee, A., Wu, W.-L., Yang, B., Huber, N., Pasca, S. P., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3440 · Cited by 1,061 · cited 11×
“However, the AAV9 serotype has several limitations in terms of more gene expression in astrocytes compared to neurons in adult animal brains, and the DNA package size.”
BackgroundInfluentialTransferrin receptor on endothelium of brain capillaries
Jefferies, W. A., Brandon, M. R., Hunt, S. V., Williams, A. F., Gatter, K. C., & Mason, D. Y. (1984) · Nature · doi:10.1038/312162a0 · Cited by 1,061 · cited 1×
“OX26, a mAb for the specific targeting of rat TfR, binds to an allosteric site on TfR that is distinct from the transferrin binding site, and does not interfere with Tf binding [131,132].”
BackgroundThree or more routes for leukocyte migration into the central nervous system
Ransohoff, R. M., Kivisäkk, P., & Kidd, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1130 · Cited by 1,052
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035
Functional recovery in parkinsonian monkeys treated with GDNF
Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P. A., Collins, F., et al. (1996) · Nature · doi:10.1038/380252a0 · Cited by 955 · cited 1×
“The glial cell line-derived neurotrophic factor (GDNF) is one of the potent agents for PD treatment because of its neuroprotective and neurotrophic effects [272,273].”
BackgroundDual microglia effects on blood brain barrier permeability induced by systemic inflammation
Haruwaka, K., Ikegami, A., Tachibana, Y., Ohno, N., Konishi, H., Hashimoto, A., Matsumoto, M., Kato, D., Ono, R., Kiyama, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13812-z · Cited by 923 · cited 1×
“microglia contribute to BBB integrity by exerting dual effects on BBB permeability, the initial protection of the BBB integrity but microglia develop into a phagocytic phenotype to increase BBB permeability as inflammation progresses [100].”
BackgroundGene therapy clinical trials worldwide to 2017: An update
Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3015 · Cited by 903 · cited 1×
“Due to the high transfection efficiency of these vectors, viral vectors have been used in many clinical trials in gene therapy [8].”
The movers and shapers in immune privilege of the CNS
Engelhardt, B., Vajkoczy, P., & Weller, R. O. (2017) · Nature Immunology · doi:10.1038/ni.3666 · Cited by 893 · cited 1×
“these sites are localized to superficial leptomeningeal vessels, parenchymal vessels, and the choroid plexus [174].”
BackgroundAstrocytes Control Synapse Formation, Function, and Elimination
Chung, W.-S., Allen, N. J., & Eroglu, C. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020370 · Cited by 839 · cited 1×
“Their main functions are to supply neurons with nutrients and to regulate synaptic activities [85].”
BackgroundLRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Hinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814
Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Holtzman, D. M., Herz, J., & Bu, G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006312 · Cited by 782 · cited 1×
“It has been reported that an apolipoprotein E (APOE) isoform influences the risk for AD, and APOE4 is known to be a strong genetic risk factor [19].”
BackgroundBertrand, N., Grenier, P., Mahmoudi, M., Lima, E. M., Appel, E. A., Dormont, F., Lim, J.-M., Karnik, R., Langer, R., & Farokhzad, O. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00600-w · Cited by 708
Knowland, D., Arac, A., Sekiguchi, K. J., Hsu, M., Lutz, S. E., Perrino, J., Steinberg, G. K., Barres, B. A., Nimmerjahn, A., & Agalliu, D. (2014) · Neuron · doi:10.1016/j.neuron.2014.03.003 · Cited by 703 · cited 1×
“Stroke Up-regulation of GLUT1 Increased BBB permeability [209] [210] [211]”
BackgroundLeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
Daneman, R., Zhou, L., Agalliu, D., Cahoy, J. D., Kaushal, A., & Barres, B. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013741 · Cited by 577
Demeule, M., Currie, J., Bertrand, Y., Ché, C., Nguyen, T., Régina, A., Gabathuler, R., Castaigne, J., & Béliveau, R. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05492.x · Cited by 557 · cited 2×
“ANG1005, consists of three paclitaxel molecules that are covalently linked to angiopep-2, and was designed to cross the BBB and blood-cerebrospinal barriers and to penetrate malignant cells via the LRP1 transport system.”
BackgroundApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Aβ Secretion
Huang, Y.-W. A., Zhou, B., Wernig, M., & Südhof, T. C. (2017) · Cell · doi:10.1016/j.cell.2016.12.044 · Cited by 528 · cited 1×
“Other reports have also shown that APOE secreted by the glia stimulates neuronal Aβ production with an APOE4 > APOE3 > APOE2 potency rank order [21].”
BackgroundDuque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.-M., Fyfe, J., Moullier, P., Colle, M.-A., & Barkats, M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.71 · Cited by 511
Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease
Yamazaki, Y., & Kanekiyo, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091965 · Cited by 451 · cited 10×
“GLUT1 on the cell membrane undergoes endocytosis and is pooled in intracellular vesicles [115,116].”
BackgroundInfluentialBiological Identity of Nanoparticles In Vivo : Clinical Implications of the Protein Corona
Caracciolo, G., Farokhzad, O. C., & Mahmoudi, M. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.08.011 · Cited by 426
Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
Pardridge, W. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00373 · Cited by 405
Anatomy and physiology of the blood-brain barrier
Serlin, Y., Shelef, I., Knyazer, B., & Friedman, A. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.01.002 · Cited by 397
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease
Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. (2008) · Neurology · doi:10.1212/01.wnl.0000312381.29287.ff · Cited by 370 · cited 1×
“In PD, which is characterized by loss of dopaminergic neurons in the substantia nigra and a decrease in dopamine levels in the striatum, the transfer of genes that encode for several enzymes such as aromatic L-amino acid decarboxylase (AADC) that converts L-dopa to dopamine [16], glutamic acid decarboxylase (GAD) that…”
BackgroundNakagawa, S., Deli, M. A., Nakao, S., Honda, M., Hayashi, K., Nakaoke, R., Kataoka, Y., & Niwa, M. (2007) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-007-9195-4 · Cited by 364
Wilson, B., Samanta, M. K., Santhi, K., Kumar, K. P. S., Paramakrishnan, N., & Suresh, B. (2008) · Brain Research · doi:10.1016/j.brainres.2008.01.039 · Cited by 363
Mapping protein binding sites on the biomolecular corona of nanoparticles
Kelly, P. M., Åberg, C., Polo, E., O'Connell, A., Cookman, J., Fallon, J., Krpetić, Ž., & Dawson, K. A. (2015) · Nature Nanotechnology · doi:10.1038/nnano.2015.47 · Cited by 360
Pre-existing Anti–Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy
Louis Jeune, V., Joergensen, J. A., Hajjar, R. J., & Weber, T. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.243 · Cited by 358
Pardridge, W. M., Buciak, J. L., & Friden, P. M. (1991) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20567-5 · Cited by 358
Onasemnogene Abeparvovec: First Global Approval
Hoy, S. M. (2019) · Drugs · doi:10.1007/s40265-019-01162-5 · Cited by 337 · cited 5×
“Actually, the AAV9 serotype is used as a vector in gene therapy for the treatment of SMA, Zolgensma, as mentioned above.”
BackgroundInfluentialBrain-targeted drug delivery by manipulating protein corona functions
Zhang, Z., Guan, J., Jiang, Z., Yang, Y., Liu, J., Hua, W., Mao, Y., Li, C., Lu, W., Qian, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11593-z · Cited by 334 · cited 1×
“The latter example is that precisely manipulating the binding pattern of brain targeted apolipoproteins on the nanoparticle surface resulted in superior brain accumulation and showed a therapeutic efficacy in a glioma tumor model [54].”
BackgroundImpact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake
Mirshafiee, V., Kim, R., Park, S., Mahmoudi, M., & Kraft, M. L. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.10.019 · Cited by 316 · cited 1×
“However, random protein adsorption can cause access to the receptor-binding pocket to be inhibited [255,256].”
BackgroundMechanisms of Brain Iron Transport: Insight into Neurodegeneration and CNS Disorders
Mills, E., Dong, X.-P., Wang, F., & Xu, H. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.09.140 · Cited by 309 · cited 1×
“TfR1 is highly expressed at the luminal side of the BBB, and promotes the uptake of iron by the brain by binding to transferrin saturated with iron [124].”
BackgroundArima, Y., Harada, M., Kamimura, D., Park, J.-H., Kawano, F., Yull, F. E., Kawamoto, T., Iwakura, Y., Betz, U. A. K., Márquez, G., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.022 · Cited by 307 · cited 2×
“In that report [187], the activation of sensory nerves by artificially weak electrical stimulation of the quadriceps or triceps muscles increased the expression of chemokines and formed vascular gates for immune cells to enter the CNS in the dorsal vessels of the third lumber spinal cord or fifth cervical spinal cord…”
BackgroundGene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Marchetti, L., & Engelhardt, B. (2020) · Vascular Biology · doi:10.1530/vb-19-0033 · Cited by 304
Blood—Brain Barrier Glucose Transporter: Effects of Hypo‐ and Hyperglycemia Revisited
Simpson, I. A., Appel, N. M., Hokari, M., Oki, J., Holman, G. D., Maher, F., Koehler‐Stec, E. M., Vannucci, S. J., & Smith, Q. R. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720238.x · Cited by 304
Microglia–blood vessel interactions: a double-edged sword in brain pathologies
Dudvarski Stankovic, N., Teodorczyk, M., Ploen, R., Zipp, F., & Schmidt, M. H. H. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1524-y · Cited by 301 · cited 2×
“Microglia has a double-edged sword in brain pathologies, which means that they survey the influx of blood-born components into the CNS to protect the brain under normal condition, but, on the other hand, their dysregulation has been implicated in the initiation and progression of neurological disorders [98,99].”
BackgroundBilang-Bleuel, A., Revah, F., Colin, P., Locquet, I., Robert, J.-J., Mallet, J., & Horellou, P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8818 · Cited by 297
Steiner, O., Coisne, C., Cecchelli, R., Boscacci, R., Deutsch, U., Engelhardt, B., & Lyck, R. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903732 · Cited by 293
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291 · cited 2×
“AAVvectors are used to transduce therapeutic genes to the CNS site for treatment of neurodegenerative disorders [12,65], and many serotypes have been developed by capsid modification strategies, such as directed evolution (Random mutation insertion, DNA shuffling, Peptide display) [214] and rational design [215], as s…”
BackgroundMethodProduction and clinical development of nanoparticles for gene delivery
Chen, J., Guo, Z., Tian, H., & Chen, X. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.23 · Cited by 274 · cited 1×
“Another strategy depends on encapsulating the nucleic acids in nanoparticles (NPs) in which the size can be tuned [76].”
BackgroundHuang, Q., Chan, K. Y., Tobey, I. G., Chan, Y. A., Poterba, T., Boutros, C. L., Balazs, A. B., Daneman, R., Bloom, J. M., Seed, C., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0225206 · Cited by 234 · cited 1×
“B transduction with/without Ly6a showed that Ly6a facilitates binding and transduction both in vitro and in vivo [198].”
Development and Function of the Blood-Brain Barrier in the Context of Metabolic Control
Haddad-Tóvolli, R., Dragano, N. R. V., Ramalho, A. F. S., & Velloso, L. A. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00224 · Cited by 226
Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment
Carrithers, M. D., Visintin, I., Kang, S. J., & Janeway, C. A. (2000) · Brain · doi:10.1093/brain/123.6.1092 · Cited by 220 · cited 2×
“Inflammation in the CNS leads to an increased expression of adhesion molecules on endothelial cells of the BBB, such as the intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and the platelet endothelial cell adhesion molecule (PECAM1) [178].”
BackgroundThe GPI-Linked Protein LY6A Drives AAV-PHP.B Transport across the Blood-Brain Barrier
Hordeaux, J., Yuan, Y., Clark, P. M., Wang, Q., Martino, R. A., Sims, J. J., Bell, P., Raymond, A., Stanford, W. L., & Wilson, J. M. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.013 · Cited by 217
Dodart, J.-C., Marr, R. A., Koistinaho, M., Gregersen, B. M., Malkani, S., Verma, I. M., & Paul, S. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409072102 · Cited by 207
Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9
Saraiva, J., Nobre, R. J., & Pereira de Almeida, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.09.011 · Cited by 201
Abadier, M., Haghayegh Jahromi, N., Cardoso Alves, L., Boscacci, R., Vestweber, D., Barnum, S., Deutsch, U., Engelhardt, B., & Lyck, R. (2015) · European Journal of Immunology · doi:10.1002/eji.201445125 · Cited by 200
Phase I Study of GRN1005 in Recurrent Malignant Glioma
Drappatz, J., Brenner, A., Wong, E. T., Eichler, A., Schiff, D., Groves, M. D., Mikkelsen, T., Rosenfeld, S., Sarantopoulos, J., Meyers, C. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2481 · Cited by 190
Caffeine protects against MPTP‐induced blood‐brain barrier dysfunction in mouse striatum
Chen, X., Lan, X., Roche, I., Liu, R., & Geiger, J. D. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05697.x · Cited by 189 · cited 1×
“PD Decrease in TJ protein expression, leaky BBB [207] Abnormal distribution of GLUT1 [208]”
BackgroundLessons learned from the clinical development and market authorization of Glybera
Bryant, L. M., Christopher, D. M., Giles, A. R., Hinderer, C., Rodriguez, J. L., Smith, J. B., Traxler, E. A., Tycko, J., Wojno, A. P., & Wilson, J. M. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.087 · Cited by 189
Neuroinflammation and blood-brain barrier changes in capillary amyloid angiopathy
Carrano, A., Hoozemans, J. J. M., van der Vies, S. M., van Horssen, J., de Vries, H. E., & Rozemuller, A. J. M. (2012) · Neurodegenerative Diseases · doi:10.1159/000334916 · Cited by 186 · cited 1×
“AD Down-regulation of glucose transporter 1 (GLUT1) [201] Down-regulation of low density lipoprotein receptor (LDLR) [203] Decreased expression and functionality of P-gp [204] Low expression of tight junction (TJ) proteins [205] Multiple sclerosis (MS) Abundance of chemokines and cytokines, leading to damage on TJ pro…”
BackgroundIn vivo genome editing improves motor function and extends survival in a mouse model of ALS
Gaj, T., Ojala, D. S., Ekman, F. K., Byrne, L. C., Limsirichai, P., & Schaffer, D. V. (2017) · Science Advances · doi:10.1126/sciadv.aar3952 · Cited by 185
Oligonucleotide therapies for disorders of the nervous system
Khorkova, O., & Wahlestedt, C. (2017) · Nature Biotechnology · doi:10.1038/nbt.3784 · Cited by 179 · cited 1×
“Moreover, Spinraza needs to be administered every four months for infant SMA patients and every six months for non-infant SMA, and there are concerns regarding the risk for infections and tissue damage with each administration [7].”
BackgroundMatsuzaki, Y., Konno, A., Mochizuki, R., Shinohara, Y., Nitta, K., Okada, Y., & Hirai, H. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2017.11.049 · Cited by 173 · cited 2×
“B failed to show CNS tropism in some mouse strains and animal species [196,197], and a specific haplotype of the lymphocyte antigen 6 complex, locus A (Ly6a) (stem cell antigen-1 [Sca-1]) has been identified as the factor required for AAV-PHP.”
BackgroundLi, J. Y., Boado, R. J., & Pardridge, W. M. (2001) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200101000-00008 · Cited by 164
Gene Therapy Tools for Brain Diseases
Ingusci, S., Verlengia, G., Soukupova, M., Zucchini, S., & Simonato, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00724 · Cited by 158
Distribution of insulin in trigeminal nerve and brain after intranasal administration
Lochhead, J. J., Kellohen, K. L., Ronaldson, P. T., & Davis, T. P. (2019) · Scientific Reports · doi:10.1038/s41598-019-39191-5 · Cited by 146 · cited 1×
“Briefly, intranasal delivery is a non-invasive method, known as the noseto-brain route, for delivering various therapeutic molecules including small molecules [283], proteins [284,285], and oligonucleotides as well [286] and gene delivery vectors [287,288].”
MethodMingozzi, F., Chen, Y., Edmonson, S. C., Zhou, S., Thurlings, R. M., Tak, P. P., High, K. A., & Vervoordeldonk, M. J. (2013) · Gene Therapy · doi:10.1038/gt.2012.55 · Cited by 138
Stealth Effect of Biomolecular Corona on Nanoparticle Uptake by Immune Cells
Caracciolo, G., Palchetti, S., Colapicchioni, V., Digiacomo, L., Pozzi, D., Capriotti, A. L., La Barbera, G., & Laganà, A. (2015) · Langmuir · doi:10.1021/acs.langmuir.5b02158 · Cited by 131
Ultrasound targeted CNS gene delivery for Parkinson's disease treatment
Fan, C.-H., Lin, C.-Y., Liu, H.-L., & Yeh, C.-K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.004 · Cited by 97
Griffin, J. M., Fackelmeier, B., Fong, D. M., Mouravlev, A., Young, D., & O’Carroll, S. J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0075-6 · Cited by 90 · cited 1×
“Several cell type specific/selective AAV-vectors have been reported (brain microvascular endothelial cells [223], astrocytes [224]).”
BackgroundAdeno-associated virus (AAV) vectors: Rational design strategies for capsid engineering
Lee, E. J., Guenther, C. M., & Suh, J. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.09.004 · Cited by 83 · cited 1×
“AAVvectors are used to transduce therapeutic genes to the CNS site for treatment of neurodegenerative disorders [12,65], and many serotypes have been developed by capsid modification strategies, such as directed evolution (Random mutation insertion, DNA shuffling, Peptide display) [214] and rational design [215], as s…”
MethodShen, L., Tenzer, S., Storck, W., Hobernik, D., Raker, V. K., Fischer, K., Decker, S., Dzionek, A., Krauthäuser, S., Diken, M., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.08.049 · Cited by 74
Xu, Julin, G., Yuanjie, Z., Hai, W., Qiushi, R., & Jianghan, C. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s17503 · Cited by 69
Belur, L. R., Temme, A., Podetz-Pedersen, K. M., Riedl, M., Vulchanova, L., Robinson, N., Hanson, L. R., Kozarsky, K. F., Orchard, P. J., Frey, W. H., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.187 · Cited by 67
Schuessler‐Lenz, M., Enzmann, H., & Vamvakas, S. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1639 · Cited by 50
Fu, C., Xiang, Y., Li, X., & Fu, A. (2018) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.12.029 · Cited by 48 · cited 1×
“Peptide derivatives of the rabies virus glycoprotein (RVG) have been exploited as delivery ligands to target the brain [242,243].”
Background
Cited by
AL Qtaish, N., Gallego, I., Paredes, A. J., Villate-Beitia, I., Soto-Sánchez, C., Martínez-Navarrete, G., Sainz-Ramos, M., Lopez-Mendez, T. B., Fernández, E., Puras, G., et al. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c02182 · Cited by 29
Pramoda, G., Verma, R. K., Kesharwani, P., & Shukla, R. (2025) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2025.127938 · Cited by 15
Althaher, A. R., & S. AL Shehadeh, R. (2024) · The Open Biomarkers Journal · doi:10.2174/0118753183367402241216115139 · Cited by 4
Metadata
- Authors
- Kimura, S., & Harashima, H.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2020-12-15
- Volume
- 12
- Issue
- 12
- Pages
- 1216
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W3110785280
- Cited by
- 65
- References
- 95
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.